Zolodrenic acid can prevent early bone loss in HIV patients on antiretroviral therapy

24 Feb 2016


Based on a Nature Comms mouse study, clinical trials in humans show zolodrenic acid can inhibit the bone loss that is common in HIV-infected patients on ART.

EurekAlert


Related Topics

Adrenal Diabetes Metabolism Obesity Cardiovascular Bone Endocrine-Disrupting Chemicals Endocrine-Related Cancer Neuroendocrinology Reproduction Steroid and Steroidogenesis Thyroid

Share this story